Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.apsb.2021.06.016 http://scihub22266oqcxt.onion/10.1016/j.apsb.2021.06.016 34249607!8260826!34249607     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Pharm+Sin+B 2022 ; 12 (4): 1591-1623 Nephropedia Template TP {{tp|p=34249607|t=2022. Recent advances in developing small-molecule inhibitors against SARS-CoV-2 |pdf=|usr=}}{{34249607}} gab.com Text Recent advances in developing small-molecule inhibitors against SARS-CoV-2 JO: Acta Pharm Sin B http://www.kidney.de/pget.php?&tw=1&pmid=34249607 #FOAvip The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across the entire world. Even though several COVID-19 vaccines are currently in distribution worldwide, with others in the pipeline, treatment modalities lag behind. Accordingly, researchers have been working hard to understand the nature of the virus, its mutant strains, and the pathogenesis of the disease in order to uncover possible drug targets and effective therapeutic agents. As the research continues, we now know the genome structure, epidemiological and clinical features, and pathogenic mechanism of SARS-CoV-2. Here, we summarized the potential therapeutic targets involved in the life cycle of the virus. On the basis of these targets, small-molecule prophylactic and therapeutic agents have been or are being developed for prevention and treatment of SARS-CoV-2 infection. Twit Text FOAVip Recent advances in developing small-molecule inhibitors against SARS-CoV-2 ????Acta Pharm Sin B http://www.kidney.de/pget.php?&tw=1&pmid=34249607 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34249607 #FOAvip English Wikipedia <ref>{{Cite pmid|34249607}}</ref> Recent advances in developing small-molecule inhibitors against SARS-CoV-2 #MMPMID34249607 Xiang R; Yu Z; Wang Y; Wang L; Huo S; Li Y; Liang R; Hao Q; Ying T; Gao Y; Yu F; Jiang S Acta Pharm Sin B 2022[Apr]; 12 (4): 1591-1623 PMID34249607show ga The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across the entire world. Even though several COVID-19 vaccines are currently in distribution worldwide, with others in the pipeline, treatment modalities lag behind. Accordingly, researchers have been working hard to understand the nature of the virus, its mutant strains, and the pathogenesis of the disease in order to uncover possible drug targets and effective therapeutic agents. As the research continues, we now know the genome structure, epidemiological and clinical features, and pathogenic mechanism of SARS-CoV-2. Here, we summarized the potential therapeutic targets involved in the life cycle of the virus. On the basis of these targets, small-molecule prophylactic and therapeutic agents have been or are being developed for prevention and treatment of SARS-CoV-2 infection. äRecent advances in developing small-molecule inhibitors against SARS-C(epmc).pdf DeepDyve Pubget Overpricing